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Axonal protein synthesis: a potential target for pain relief?
Ilona Obara1,2, Sandrine M Ge´ranton1 and Stephen P Hunt1
Research on the role of axonal protein synthesis in the
regulation of nociceptive mechanisms has grown significantly
over the past four years. Recent advances include evidence
that local translation of mRNA can occur in adult primary
afferents under the control of the mammalian target of
rapamycin (mTOR) and the extracellular signal-regulated
kinase (ERK) signaling pathways. Studies investigating the
effect of mTOR and ERK pathway inhibitors in a number of pain
models suggest that these signaling pathways may act
independently, depending on the type of sensory afferents
studied. The evidence that nociception can be regulated at the
level of mRNA translation in nociceptors has important
implications for the understanding of the mechanisms of
nociceptive plasticity and therefore for therapeutic
interventions in chronic pain conditions.
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Introduction
The idea that mature adult axons have the capacity for
local protein synthesis independently from the cell body
has gradually been gaining acceptance. Piper and Holt [1]
reflected that the demands of an axonal process of up to
one meter in length, as in human primary sensory neurons,
would be extremely difficult to fulfill just relying purely on
proteins synthesized in the neuronal cell body and trans-
ported along the axon. Even using fast axoplasmic trans-
port (50–200 mm/day), proteins would take hours or days
to arrive at the distal segments of the axon embedded
within peripheral tissues. Local mRNA translation in
axons would therefore appear to have enormous advan-
tages and permit a reasonably rapid response to changing
conditions. Evidence for local mRNA translation is
particularly strong in the growth cones of developing axons
or in regenerating adult sensory axons, where local protein
synthesis is seen as a response to environmental cues
[2–4,5,6]. Recently, studies have suggested that local
mRNA translation occurs in adult primary afferent axons
and is thought to be functionally important in nociception
[7,8,9–13,14,15,16].
Nociceptors and nociception
Primary afferents are divided into myelinated A-fibers that
signal noxious or innocuous stimuli and unmyelinated C-
fibers that are largely nociceptors. A-nociceptors mediate
‘first’ pain perceived as rapid and sharp and C-fibers signal
‘second’ pain, delayed, diffuse, and dull [17,18]. Nocicep-
tors innervate the skin, muscle, joints, and viscera that
selectively respond to noxious or potentially tissue-dama-
ging stimuli. The most common nociceptor in the skin is
the C-polymodal nociceptor, which responds to thermal,
mechanical, and chemical stimulation [19]. Skin also con-
tains modality-selective nociceptors such as C-heat and C-
mechano-cold nociceptors while joints and viscera are
innervated by C-nociceptors responding to both mechan-
ical and chemical stimulation [18]. Finally, a subset of C-
nociceptors, chemosensitive but relatively insensitive to
mechanical stimuli in the absence of tissue injury, is
referred to as ‘silent’ nociceptors, or as mechanically insen-
sitive afferents [18]. One essential characteristic of most
nociceptors is that they sensitize which results in a
reduction in their activation threshold and an increase in
the magnitude of the response to noxious stimulation
[17,18]. For example, inflammation or tissue injury pro-
vokes the release of a variety of cytokines (i.e. interleukin-
6, IL-6) and growth factors (i.e. nerve growth factor, NGF)
that act on and increase the sensitivity of a subset of
nociceptors to noxious stimulation resulting in primary
hyperalgesia [18]. However, an important subset of A-
nociceptors and some C-nociceptors, terminating away
from the site of injury, do not sensitize but contribute to
the increased mechanical sensitivity in the undamaged
area around the site of injury resulting in secondary hyper-
algesia [20]. This secondary spread of sensitivity away
from the site of primary injury is a product of central
processing. Thus injury responsive C-fibers set up central
sensitization in the dorsal horn, a mechanism that leads to
the amplification of the subsequent response of Ad-fibers
and some Ab-fibers (involved in touch), resulting in
increased pain or enhanced sensitivity to pinprick and
light touch [20,21]. Below we summarize the evidence
that local protein synthesis may regulate the excitability of
A-nociceptors and C-nociceptors but through different
signaling pathways.
Translation and sensory axons
Translation of mRNA takes place in three steps,
initiation, elongation, termination, and is a rapid and
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reversible process spatially controlled by a large number
of upstream kinases [15]. The activity of these kinases can
be modulated by selective inhibitors or by endogenous
signaling factors that act on these pathways (Figure 1).
The major protein kinase that regulates initiation of
translation is the mammalian target of rapamycin
(mTOR), a critical downstream target of the phosphati-
dylinositol-3 kinase (PI3K) pathway, which signals to
eukaryotic initiation factor (eIF) eIF4E and eIF4G and
the eIF4E binding protein (4EBP) [15,22]. mTOR plays a
major role in regulating cell growth and metabolism in
eukaryotic cells and forms two distinct complexes:
mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2) [22,23] (details in Figure 1a and b).
Another kinase regulating mRNA translation is the extra-
cellular regulated kinase (ERK; Figure 1c). ERK controls
the initiation of translation by acting on eIF4E but can
also indirectly engage mTORC1 signaling through tuber-
ous sclerosis complex 2 (TSC2) [15,24].
In the periphery, the necessary machinery for the mRNA
translation is present in peripheral sensory axons
[1,8,13,16,25]. Ribosomes, while difficult to detect using
electron microscopy, have been observed using immuno-
histochemical approaches and are derived from the cell
body although it was recently shown that ribosomes can
be transferred from Schwann cells to axons [1,26,27].
There is also evidence for the transport of subsets of
mRNA traveling down the axon in association with RNA
binding and transport proteins such as staufen and fragile
X mental retardation protein [28,29].
Local translation and nociception
Several studies have concluded that mRNA translation in
sensory axons plays a role in regulating peripheral noci-
ception [7,8,9–13,14,15,16]. Both mTOR and ERK
pathways are critical for neuronal plasticity and it is
suggested that both are activated within axons after
noxious stimulation, although possibly through different
mechanism and in different type of sensory afferents
[7,8,13,14,16] (Figures 1 and 2).
Specifically, it has recently been suggested that two major
algogens, IL-6 and NGF, signal through two distinct
pathways to enhance translation in sensory neurons by
converging onto the eIF4F complex [14]. While sensit-
ization of nociceptors by IL-6 or coinjection of IL-6 and
NGF produces enhanced mechanical hypersensitivity
that can be reduced by blockers of translation (e.g.
anisomycin, 4EGI1) or of the ERK pathway (e.g.
U0126) [14], in vitro activation of dissociated dorsal root
ganglion (DRG) neurons by NGF is blocked by the
mTORC1 inhibitor rapamycin, although this was not
confirmed in vivo [14] (Figure 1). These results suggest
that ERK-driven local mRNA translation may support
peripheral sensitization. However, while local NGF injec-
tion causes sensitization, the evidence that NGF activates
local mRNA translation in vivo has not been presented
[14].
In vivo evidence is even more puzzling. The hallmark of
peripheral sensitization is increased thermal sensitivity
thought to be supported by ERK activation at the level of
the cell body and by a subsequent synthesis of the
TRPV1 receptor and its transport to the axon terminals
in inflamed cutaneous tissue, but not by local translation
[30]. Moreover, thermal sensitivity of inflamed tissue is
not reduced by local injection of mTOR inhibitors, rapa-
mycin or its analog temsirolimus — CCI-779 [8,13],
suggesting that local translation does not support periph-
eral sensitization. Although intrathecal injection of rapa-
mycin has been shown to produce variable effects on
thermal thresholds, this may be the result of a direct
modulation of central processing [7,9,10,12]. In contrast
to thermal hyperalgesia, increased mechanical sensitivity
following inflammation has been shown to be influenced
by local inhibitors that influence both mTOR and ERK
pathways [7,8,9–13,14]. How is it possible that thermal
and mechanical sensitivity can be independently
regulated by local mRNA translation in nociceptors? It
may be that thermal and mechanical stimulation activate
different nociceptor populations [33], but given the phys-
iological characterization of C-nociceptors this seems
unlikely. Alternatively, there may be direct modulation
of molecular determinants of mechanosensation in
primary afferent nociceptors.
Another explanation arose from the study of the distri-
bution of the translational apparatus in primary afferents.
Specifically, one of the active forms of mTOR (phos-
phorylated at serine 2448 [31]) and other downstream
components of the translational machinery were localized
to subsets of myelinated sensory fibers, and also to a small
number of unmyelinated fibers in rodent cutaneous tissue
[7,8,13,16]. In line with this evidence, electromyo-
graphic studies showed that rapamycin reduced the sen-
sitivity of myelinated A-nociceptors [7,8] also known to
be important for the increased mechanical sensitivity that
follows injury (i.e. secondary hyperalgesia) [20]. Beha-
vioral studies on capsaicin model further confirmed that
local treatment with mTOR inhibitors (i.e. spinal or
intraplantar administration of rapamycin or CCI-779)
blunted the heightened response to mechanical stimu-
lation that develops only around the site of injury
(mediated by capsaicin-insensitive A-nociceptors), while
the acute pain (transmitted by capsaicin-sensitive poly-
modal A-nociceptors and C-nociceptors) was entirely
unaffected [7,8,13]. It is important to note that these
A-fibers and probably the small set of C-fibers that
contribute indirectly to increased mechanical sensitivity
do not sensitize and that the sensitivity of these fibers is
maintained by ongoing mTOR-mediated local protein
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Regulation of mRNA translation in primary afferents. Translation of mRNA is controlled by a large number of kinases. mTORC1 (a): contains raptor, is
sensitive to the selective inhibitor rapamycin/CCI-779 that binds to FKBP12 and is controlled via the PI3K/Akt/mTOR pathway [22,23]. mTORC2 (b):
contains the protein rictor, is resistant to rapamycin/CCI-779 and is thought to modulate growth factor signaling by phosphorylating Akt kinases at serine
473 [22,23]. Inhibition of mTORC1 with rapamycin/CCI-779/Torin1 (a) or mTORC2 with Torin1 (b) in primary afferents prevents these kinases from
phosphorylating its target proteins and thus presumably prevents the initiation of CAP dependent translation of mRNAs [7,8,13]. Phosphorylation of
4EBP, which is a negative regulator of eIF4F complex formation, leads to its dissociation from eIF4E and binding of eIF4E to eIF4G. While the
phosphorylation of 4EBP have been shown to mainly regulate the CAP translation of so-called eIF4E sensitive mRNAs characterized by long and complex
50UTR, the activation of p70S6K has been linked to the CAP translation of subpopulations of mRNAs carrying a 50 terminal oligopyrimidine tract (50 TOP),
such as ribosomal proteins, poly(A) binding protein and translation elongation factors required for new protein synthesis. It has been suggested that in vitro
NGF signals to the translational machinery through eIF4G, resulting in rapid changes in mRNA translation in sensory neurons [14]. In contrast to NGF, IL-6
signals to the translational machinery through the ERK/Mnk/eIF4E signaling pathway and this is inhibited in primary afferents by the selective inhibitor of
the MAPK/ERK kinase — U0126 [14] (c). In addition, ERK phosphorylation can lead to TSC1/TSC2 dissociation and impairment of the ability of TSC2 to
inhibit mTORC1 signaling [24]. In contrast, phosphorylation of TSC2 by AMPK results in the activation of TSC1/TSC2 and subsequent inactivation of
mTORC1 [35] (d). Thus, in vitro AMPK activation by metformin/A769662 in sensory neurons leads to inhibition in mTORC1 activity [35] and eIF4F complex
formation [16]. In vivo AMPK activation by metformin inhibits nascent protein synthesis in damaged nerve [16].
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synthesis (Figure 2). In fact, recently a group of low
threshold C-fibers that do not sensitize but contribute
to post-injury mechanical hypersensitivity was identified
[21,32,33].
Taken together, the emerging data imply that mTOR-
mediated translation is primarily restricted to subsets of
A-fibers and only some C-fibers while ERK mediated
local mRNA translation is found in C-fibers [7,8,13,14].
Locally administered mTOR inhibitors reduce mechan-
ical sensitivity, in part, by reducing the sensitivity of A-
nociceptors [7,8,13]. In contrast, mTOR is largely
absent from C-fibers and primary sensitization, that is
generated by these nociceptors, is to a great extent
unimpaired by mTOR inhibitors but not by ERK inhibi-
tors [14] (Figure 2).
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Regulation of the sensitivity of different type of sensory afferents by mTOR and ERK signaling pathways. (a) Tissue injury provokes the release of a
variety of cytokines (i.e. IL-6) and growth factors that increase the sensitivity of a subset of C-nociceptors to noxious stimulation resulting in primary
hyperalgesia [18]. This increased sensitivity of C-nociceptors is reduced by blockers of translation (e.g. anisomycin, eEGI1) or of the ERK pathway
(e.g. U0126) [14]. mTOR is largely absent from C-fibers and primary hyperalgesia is unimpaired by mTOR inhibitors [7,8,13]. (b) An important subset
of A-nociceptors (and some C-nociceptors), terminating away from the injury and expressing mTOR [7,8,13], do not sensitize but contribute to the
increased mechanical sensitivity seen in the undamaged area surrounding the site of injury. This phenomenon is called secondary hyperalgesia and is
a product of central processing [20]. Administration of mTORC1 or/and mTORC2 inhibitors (e.g. rapamycin, CCI-779, Torin1) reduces mechanical
sensitivity, in part, by reducing the sensitivity of A-nociceptors [7,8,13]. Also AMPK activators (e.g. metformin, A769662) decrease secondary
hyperalgesia [14].
www.sciencedirect.com Current Opinion in Pharmacology 2012, 12:42–48
The damaged peripheral nerve, local
translation and chronic pain
Amplification of capsaicin-insensitive A-fibers signals by
sensitized dorsal horn neurons accounts for the increased
mechanical sensitivity to noxious stimulation and hyper-
sensitivity to non-noxious stimulation that are clinical
features of chronic pain, particularly neuropathic pain
resulting from the injury of peripheral nerve [34]. There
is recent evidence for reorganization of translation path-
ways and machinery in damage nerve that includes
enhanced mTOR activity and phosphorylation of its
downstream targets and increased eIF4F complex for-
mation [16]. Given that: first, subsets of A-nociceptors
express mTOR [7,8,13], second, in vitro rapamycin
amplified the electrical activation threshold of Ad-fibers
in dorsal roots [7]; three, peripheral, spinal or systemic
injection of rapamycin or CCI-779 inhibited the acti-
vation of downstream targets of mTORC1 in dorsal roots
and dorsal horn [7,8,13] it is not surprising that
mTORC1 inhibitors substantially alleviated persistent
pain states. Specifically, inhibition of mTORC1 with
rapamycin or CCI-779 locally (spinal, intraplantar) or
systemically reduced mechanical hypersensitivity in neu-
ropathic pain, in part, by reducing the sensitivity of A-
nociceptors [7,8,13]. In addition, it has been shown that
50adenosine monophosphate-activated protein kinase
(AMPK) activator, metformin, led to mTOR inhibition
and a reduction in translation initiation [35] (Figure 1d).
In rodents metformin and A769662 also inhibited nascent
protein synthesis in damage nerve and reduced mechan-
ical hypersensitivity in neuropathic pain [16].
Rapamycin and its analogs (e.g. CCI-779) have been used
clinically as anticancer and immunosuppressant drugs and
have a relatively mild side-effect profile that would support
their long-term treatment for chronic pain [36]. Indeed,
chronic systemic administration of CCI-779 did not influ-
ence the body weight or locomotor co-ordination or induce
neural toxicity when administered daily for 6 days. Most
importantly, chronic systemic treatment with CCI-779
inhibited the mTORC1 pathway in sensory axons and in
dorsal horn and reduced mechanical and cold hypersensi-
tivity after peripheral nerve injury without affecting the
nociceptive threshold in naive controls [13]. In addition,
Torin1, a novel ATP-competitive inhibitor targeting both
mTORC1 and mTORC2 pathways [37], reduced the
response to mechanical and cold stimuli in neuropathic
pain after its chronic systemic administration [13].
Recent observations suggest that increased local syn-
thesis of ion channels and receptors in the peripheral
axons of DRG neurons and in the neuroma of the
damaged nerve could facilitate nociceptive signal gener-
ation and spontaneous discharge after nerve injury. In
fact, it was reported that injury resulted in elevated axonal
excitability and increased NaV1.8 in sciatic nerves
suggesting that axonal accumulation of NaV1.8 mRNA
may play a role in the pathogenesis of neuropathic pain
[38]. However, as sensitivity to blockers of mRNA trans-
lation was not reported, the precise function of local
protein synthesis as a target for therapeutic intervention
in chronic pain still needs to be identified.
Conclusions and future directions
The available evidence implies that local mRNA trans-
lation can occur in primary afferents under the control of
the mTOR and ERK pathways. One form of activated
mTOR is restricted to A-nociceptors and a small subset of
C-fibers that signal the secondary changes in sensitivity
following injury while ERK modulated local protein
synthesis regulates the sensitization of C-nociceptors
by inflammatory mediators [7,8,13,14]. These findings
emphasize, therefore, the importance of the mTOR and
ERK pathways as a potential target for pain control.
However, despite the axonal localization of the transla-
tional machinery and evidence for its functional implica-
tion in nociception, it remains unclear which mRNAs are
transported and translated in axons. In vitro studies on
developing or regenerating axons listed several thousand
potential transcripts including cytoskeletal, mitochon-
drial and signaling proteins. In a comparison microarray
study embryonic and adult DRG axons were found to
contain a significant number of transcripts that are
uniquely enriched at each developmental stage, with
over 1100 transcripts present only in embryonic and over
1400 present only in adult axons [39]. In a second in vitro
study, using a sequential analysis of gene expression
(SAGE) analysis of sympathetic axons it was shown that
over 11 000 transcripts could be detected. Myo-inositol
monophosphate-1 mRNA, chosen for further analysis,
was shown to be under the control of exogenously applied
NGF [40]. In another in vitro study acute inhibition of
protein synthesis with emetine or cyclohexamide in sym-
pathetic axons resulted in a decrease in the membrane
potential of axonal mitochondria suggesting that the
axonal membrane potential may also be indirectly
regulated by local translation of mRNA [41,42]. However,
comparable in vivo studies have not been published and
the precise mechanism for pain relief via modulation of
axonal protein synthesis still remains to be determined.
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